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The 7th European Mucosal Immunology Group meeting was held in 
Amsterdam, in the beautiful venue of the Royal Tropical Institute, from 
the 29th September to the 2nd October 2010 and attracted 300 
delegates. This report summarizes some of the highlights of the 
conference. The meeting started with a fascinating talk by 
Reina Mebius from the VUMC Amsterdam, who presented her work 
on the development of the lymphoid tissue in the murine gut. 
Illustrated by confocal microscopy images, she described the 
important role of lymphotoxin for the development of Peyer's patches 
(PP) and intestinal lymph nodes (LN). The first immune clusters in the 
murine gut start to appear by day 13. Lymphoid tissue inducer (LTi) 
cells express Ltαß which interacts with the LT receptor on stromal 
cells, which subsequently release chemokines that attract more 
immune cells into the clusters. Cluster formation is dependent on 
CXCR5 and CXCL13, since knock-out (KO) mice for these markers 
show no immune clusters due to a lack of CD4+ CXCR5+ and 
CD4+CXCL13+ LTi cells. Reina Mebius also focused on retinoic acid 
(RA) during her talk. The importance of RA in the immune cluster 
formation is evident since retinaldehyde dehydrogenase type 2 
(RALDH2) KO mice (missing the enzyme that converts retinaldehyde 
into RA) have no intestinal LN formation on embryonic day 13.5. It 
was proposed that neurones reaching towards the immune clusters are 
the source of RA which then stimulates mesenchymal precursor cells to 
express CXCL13 which is crucial for LN formation. However, CCL21 
might be able to compensate for the loss of CXCL13 to some extend, 
since it can stimulate mesenchymal precursor cells as well. Ifor 
Williams (Emory University, Atlanta) gave an overview of M cell 
function and explained the important role of RANKL (Receptor 
Activator for Nuclear Factor κ B Ligand) which facilitates LN 
development but also determines the differentiation and number of M 
cells in the gut. RANKL KO mice show a 70%-decrease in M cell 
numbers and recombinant RANKL (rRANKL) can restore the number of 
M cells in these mice. rRANKL treatment leads to a diffuse distribution 
of M cells on villi in the small intestine and to a higher rate of bacterial 
translocation in these animals. Ifor Williams therefore hypothesized 
that rRANKL treatment might be a strategy to temporarily increase M 
cell numbers in the gut which might intensify the immune response to 
oral vaccinations. An important topic in the following session was RA 
and its effect on dendritic cells (DCs). Rosalie Molenaar (VUMC 
Amsterdam) talked about RALDH in murine DCs and the role for RA for 
Foxp3+ regulatory T cells (Treg) function and imprinting of gut homing 
receptors. RALDH expression in migratory CD103+ DCs and 
mesenteric lymph node (MLN) stromal cells is controlled by dietary 
intake of vitamin A; it is, however, not dependent on signaling via Toll-
like receptors. RALDH activity is markedly decreased in mice that are 
fed a vitamin A deficient diet. Besides mucosal DCs and MLN stromal 
cells, RALDH activity is mainly detectable in intestinal epithelial cells 
and neurons. Ilaria Spadoni (European Institute of Oncology, Milan) 
presented her work on thymic stromal lymphopoetin (TSLP). This 
cytokine is produced by e.g. epithelial cells and DCs and induces 
STAT5 expression. It favors a Th2 differentiation and down-regulates 
interleukin-12 production by T cells. Ilaria Spadoni found TSLP to be 
down-regulated in patients with Crohn’s disease. Mice deficient in TSLP 
are prone to helminth infections and develop very severe colitis after 
DSS challenge which is mediated by increased numbers of CD4+IFNγ+ 
and CD4+IL17+ cells. Therefore, TSLP seems to have anti-
inflammatory effects in mouse models of colitis that are Th1 and Th17 
driven. William Agace (University of Lund) spoke about RA and gut 
DCs. CD103+ DCs are the cells that efficiently imprint gut homing 
receptors and are the main migratory lamina propria DC population. 
Murine CD103+ DCs metabolise RA; mice fed a vitamin A deficient diet 
have no decrease of this cell population. However, RALDH activity is 
drastically reduced in the gut and CD8+ lymphocytes lack expression 
of the homing receptors CCR9 and α4β7 integrin. William Agace found 
the RA concentration to be high in bile and speculated that it might be 
an important source for DCs that imprint gut homing receptors. 
Thaddeus Stappenbeck (Washington University) presented results 
on inflammatory bowel disease and autophagy. Mutations in the 
autophagy-related gene ATG16L is one of the genetic risk factors for 
developing Crohn’s disease. He showed that mice and humans with 
variants of the ATG16L gene have abnormal and dismorphic Paneth 
cells, loss of the secretory cellular machinery and a diffuse distribution 
of lysozyme. Since the infection with a murine Norwalk-like virus (a 
pathogen present in most animal facilities) is required for the observed 
defect in autophagy in mice, he proposed a virus might also contribute 
to the pathology in IBD patients. Emanuel Berger (Technical 
University Munich) gave a very interesting talk on mitochondrial stress 
mechanisms in human colitis and murine colitis models. In T cell 
transfer colitis in mice, epithelial cells have an increased level of 
proteins associated with stress in the endoplasmatic reticulum (ER) 
and the mitochondria. He pointed out that in colitis models and IBD, 
the ER chaperone GRP78 as well as the mitochondrial stress-
associated chaperonin, Cpn60, a member of the heat shock protein 
family, are highly expressed under inflammatory conditions. In 
addition, the protein kinase R (PKR) signaling pathway leading to the 
expression of Chop60, seems to play a role in intestinal inflammation, 
since pkr KO mice do not develop DSS colitis. Manon Wildenberg 
(Leiden University Medical Centre) brought the attention back to 
autophagy. She presented her findings of increased T cell proliferation 
in mixed lymphocyte reactions (MLR) when the autophagy-related 
genes ATG16L1 and IRGM in the stimulating DCs were knocked down 
by using siRNA. These DCs showed no change in the expression of 
accessory markers CD80, CD83 and CD86; neither was the cytokine 
secretion altered after the knock-down. However, imaging of these 
ATG16L1low and IRGMlow DCs revealed a change in cell shape and an 
increased polarization of the DCs towards T cells in MLRs resulting in a 
more intimate and longer interaction with the T cells. Manon 
Wildenberg further demonstrated that DCs defective in autophagy 
stimulated T cells to a higher production of IL-17 compared to 
controls. These results might help us to understand how defects in 
autophagy in IBD patients are related to a pronounced Th17 response. 
The session on regulation in the gut by T cells started with a talk from 
Oliver Pabst (Medizinische Hochschule Hannover) who focused on 
intestinal tolerance and how the migration of DCs and T cells is crucial 
for this process. CCR7 KO mice show no oral tolerance. In these mice, 
DCs in the villi cannot migrate towards the MLN. By using Two-photon 
microscopy, Oliver Papst’s team investigated which DC populations 
move in the intestinal lymph and found that mainly CD11c+CD103+ 
DCs but not CXCR1+ DCs migrate via the lymph. Since CD103+ DCs 
also imprint gut homing receptors on T cells, he concluded that this DC 
population is the main migratory DC population which stimulates T 
cells in the MLN. Gut homing of T cells is a prerequisite for oral 
tolerance as α4β7 integrin KO mice and MAdCAM KO mice do not 
develop tolerance to ovalbumin challenge. The transfer of α4β7 
integrin + T cells into α4β7 integrin KO mice restored the ability to 
develop oral tolerance. During the talk, the role of Foxp3+ Tregs for 
oral tolerance was emphasized as well. Tregs are found to appear in 
increased numbers after antigen challenge in the lamina propria but 
only to a small extend in the MLN. Expression of CX3CR1 on DCs in the 
lamina propria is essential for expansion of Tregs and transfer of 
CX3CR1+ DCs into CX3CR1 KO mice restores the expansion of Tregs in 
the lamina propria and also oral tolerance. The following talk was 
given by Mark Travis (University of Manchester). His work 
concentrates on intestinal DCs and transforming growth factor-β 
(TGFβ). This molecule is secreted as an inactive complex and needs 
cleavage before to gains its immunoregulatory properties. The 
molecule that cleaves TGFβ is yet unknown but Mark Travis showed 
results that suggest the integrin αvβ8 on CD103+ DCs might be 
important. As already published by Travis, mice lacking αvβ8 suffer 
from autoimmunity; CD103+ DCs are potent inducers of Tregs and 
able to activate TGFβ. Travis showed data that treatment with antibody 
against TGFβ in mice abrogates the ability of CD103+ DCs to induce 
Treg development and CD103+ DCs in αvβ8 KO mice were unable to 
activate TGFβ. Therefore, he proposed that αvβ8 integrin on CD103+ 
DCs is able to activate TGFβ which subsequently differentiates naïve T 
cells into Foxp3-expressing Tregs. Pim Koelink (Utrecht University) 
focused entirely on collagen breakdown products and how they 
activate neutrophils in the course of IBD. One of these molecules is 
proline-glycine-proline (PGP), a peptide which leads to chemotaxis of 
neutrophils in the inflamed gut. PGP is formed during collagen 
breakdown by matrix-metalloproteinases 8 and 9 and prolyl 
endopeptidase which are abundant in inflamed tissue. Mice treated 
with antibodies against PGP suffered from less weight loss and disease 
activity in the DSS colitis model. PGP might therefore be a target in 
the treatment of IBD.  
In the following session on Celiac disease, Ludvig Sollid (University of 
Oslo) gave an overview on the genetic risk factors of the condition and 
explained that the enzyme transglutaminase cleaves α2-gliadin into a 
33-aminoacid long peptide which has six T cell epitopes. These 
epitopes are recognised by reactive T cells that mediate the strong Th1 
response in Celiac disease. Sollid’s group also studies the anti-
transglutaminase (TG) antibodies, an important diagnostic marker for 
the disease, and showed that these Abs are dependent on gluten in 
the diet. They were further able to demonstrate that approximately 
10% of CD138+ plasma cells in the gut were TG-specific CD138+ in 
Celiac patients. However, upon the omission of gluten from the diet, 
these specific plasma cells disappear. Anne Kozijn (Erasmus Medical 
Centre, Rotterdam) presented recent work on a mouse model of Celiac 
disease. She used transgenic mice which are deficient for MHC-II and 
transgenic for human HLA-DQ2 and the gliadin-γ1 specific T cell 
receptor (TCR). She showed that all the T cells in these mice express 
the TCR specific for deamidated gliadin-γ1. The CD4+ T cells of the 
DQ2.gliadin-TCR mice were isolated and injected to single DQ2 mice. 
However, upon gliadin challenge, only T cell proliferation in the spleen 
could be detected, none in the MLN or the gut. Why these mice do not 
have gliadin-reactive T cells in the gut needs further investigation. One 
of the presentations focusing on probiotics was given by Laurent 
Favre (Nestec Research Centre, Lausanne) who used complexes of 
secretory IgA (sIgA) and Bifidobacterium lactis to study the adhesion 
to intestinal epithelial cells in vitro and TSLP production in mice. He 
found that sIgA+ B. lactis bacteria together induced more IgA 
production than the bacteria alone. Mice treated with the complex also 
had higher anti-LPS IgG titers after immunization with Salmonella 
typhimurium compared to controls. How the sIgA-bacteria-complex 
mediates immune stimulation and how specific the process is remains 
unclear. Some insight into how the probiotic strain Lactobacillus 
paracasei acts on the immune system was provided by Marie-Anne 
von Schillde (Technical University Munich). She convincingly 
demonstrated that this strain expresses the protein lactocepin which 
degrades the proinflammatory molecule interferin-inducible protein 
(IP)-10 in vitro. Lactocepin is cell-wall associated and also secreted 
protease. It was found to have no effect on tight junctions and did not 
affect the viability of intestinal epithelial cells. Therefore, Lactocepin 
was identified as an important probiotic structure of L. paracasei. The 
meeting was closed by Severine Vermeire (Catholic University of 
Leuven) with a summary of current and future clinical approaches to 
IBD. She pointed out that although more and more research is taken 
from bench to bedside, the clinical situation is often more complex 
than in vitro data suggest. She highlighted the importance of research 
into genetic factors in IBD and how these factors might help to predict 
which therapies are most appropriate for individual patients. The 7th 
EMIG meeting was certainly a very successful and interesting meeting 
which showed a broad spectrum of human and murine research into 
mucosal immunology. The next EMIG meeting will take place from the 
10th-12th of October 2012 in Dublin. 
